Myriad Genetics (MYGN) Price & Analysis

Compare

393 Followers

MYGN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.81 - $29.30

Previous CloseN/A

Volume154.82K

Average Volume (3M)1.66M

Market Cap

$492.23M

Enterprise Value$531.30M

Total Cash (Recent Filing)$91.80M

Total Debt (Recent Filing)$157.60M

Price to Earnings (P/E)―

Beta1.56

Next Earnings

Jul 31, 2025

EPS Estimate

>-0.01

Last Dividend Ex-Date

Jul 01, 2009

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding92,177,380

10 Day Avg. Volume978,646

30 Day Avg. Volume1,655,845

Financial Highlights & Ratios

PEG Ratio-0.22

Price to Book (P/B)0.65

Price to Sales (P/S)0.00

P/FCF Ratio-13.00

Enterprise Value/Market Cap1.08

Enterprise Value/Revenue0.16

Enterprise Value/Gross Profit0.91

Enterprise Value/Ebitda-2.04

Forecast

1Y Price Target

$8.64

Price Target Upside61.80% Upside

Rating ConsensusHold

Number of Analyst Covering13

Myriad Genetics News

See All News >

Bulls Say, Bears Say

Bulls Say

Core FranchiseMYGN has a solid core franchise in esoteric testing - namely hereditary cancer and reproductive health - where innovation and branding can lead to growth above traditional labs.

InnovationA partnership with PATHOMIQ has been launched to advance AI-powered testing solutions, which is expected to accelerate the timeline for gaining Level 1 evidence for Prolaris.

LeadershipCEO Raha is acting with urgency, and focused on righting the ship.

Bears Say

CompetitionIntensifying competitive pressures in NIPT and in hereditary cancer testing are limiting growth potential longer term.

Market ExpectationsThe reduced price target from $15 to $7 indicates lowered expectations for the company's performance.

Revenue GuidanceManagement has lowered the revenue guidance by $35 million to reflect ongoing challenges, indicating uncertainty in achieving future targets.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

4.46% Insiders

24.07% Mutual Funds

24.38% Other Institutional Investors

19.69% Public Companies and Individual Investors

Detailed Ownership Overview >

MYGN FAQ

What was Myriad Genetics’s price range in the past 12 months?

Myriad Genetics lowest stock price was $3.81 and its highest was $29.30 in the past 12 months.

What is Myriad Genetics’s market cap?

Myriad Genetics’s market cap is $492.23M.

When is Myriad Genetics’s upcoming earnings report date?

Myriad Genetics’s upcoming earnings report date is Jul 31, 2025 which is in 17 days.

How were Myriad Genetics’s earnings last quarter?

Myriad Genetics released its earnings results on May 06, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.055 by $0.025.

Is Myriad Genetics overvalued?

According to Wall Street analysts Myriad Genetics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Myriad Genetics pay dividends?

Myriad Genetics pays a Monthly dividend of $1.75 which represents an annual dividend yield of N/A. See more information on Myriad Genetics dividends here

What is Myriad Genetics’s EPS estimate?

Myriad Genetics’s EPS estimate is >-0.01.

How many shares outstanding does Myriad Genetics have?

Myriad Genetics has 92,177,380 shares outstanding.

What happened to Myriad Genetics’s price movement after its last earnings report?

Myriad Genetics reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.055. Following the earnings report the stock price went down -41.265%.

Which hedge fund is a major shareholder of Myriad Genetics?

Currently, no hedge funds are holding shares in MYGN

Myriad Genetics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-13.84%

Trailing 12-Months

Asset Growth

-9.40%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Myriad Genetics

Myriad Genetics, Inc. (MYGN) is a leading molecular diagnostic company that develops and markets genetic tests designed to assess an individual's risk of developing diseases, guide treatment decisions, and improve patient outcomes. Operating primarily in the healthcare sector, Myriad Genetics focuses on personalized medicine, particularly in oncology, women's health, and mental health. The company's core products include a range of genetic, genomic, and hereditary cancer tests, which are utilized by healthcare professionals to tailor medical treatment to individual patients.

MYGN Company Deck

MYGN Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Negative

The earnings call highlighted challenges with revenue decline and specific issues with GeneSight and hereditary cancer testing. However, some positive aspects included growth in prenatal testing and progress in the product pipeline. The company's guidance was revised downwards, indicating significant challenges ahead.Read More>

MYGN Stock 12 Month Forecast

Average Price Target

$8.64

▲(61.80%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","16":"$16","29":"$29","9.5":"$9.5","22.5":"$22.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,9.5,16,22.5,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.46,5.501538461538462,6.543076923076923,7.584615384615384,8.626153846153846,9.667692307692308,10.709230769230768,11.75076923076923,12.792307692307691,13.833846153846153,14.875384615384615,15.916923076923077,16.95846153846154,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.46,4.781538461538462,5.103076923076923,5.424615384615385,5.746153846153846,6.067692307692308,6.389230769230769,6.710769230769231,7.032307692307693,7.353846153846154,7.6753846153846155,7.9969230769230775,8.31846153846154,{"y":8.64,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.46,4.424615384615384,4.389230769230769,4.3538461538461535,4.318461538461539,4.283076923076923,4.247692307692308,4.212307692307692,4.176923076923077,4.141538461538461,4.1061538461538465,4.070769230769231,4.035384615384615,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.76,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.97,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.6,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.33,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.03,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.99,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.69,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.71,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":12.67,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.73,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.13,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >